Nanobodies efficiently neutralize SARS-CoV-2 in cells
Reviewed by Emily Henderson, B.Sc.Nov 5 2020
Two separate studies have identified nanobodies – which could be produced less expensively than monoclonal antibodies – that bind tightly to the SARS-CoV-2 spike protein and efficiently neutralize SARS-CoV-2 in cells. "The combined stability, potency, and diverse epitope engagement of our … nanobodies … provide a unique potential prophylactic and therapeutic strategy to limit the continued toll of the COVID-19 pandemic," write authors on one paper (Michael Schoof et al.)
- SARS-CoV-2 spike D614G variant exhibits enhanced replication and transmissibility
- SARS-CoV-2 T-cell immunity is retained for at least six months
- Ethacridine blocks SARS-CoV-2 with a distinct mode of action
In the battle against COVID-19, monoclonal antibodies that bind to the spike protein of the SARS-CoV-2 virus are being explored as potential therapeutics. These show promise but must be produced in mammalian cells and need to be delivered intravenously. By contrast, single-domain antibodies called nanobodies can be produced in bacteria or yeast and their stability gives the potential for aerosol delivery. In two separate studies, Michael Schoof et al. and Yufei Xiang et al. describe the identification of nanobodies that efficiently neutralize SARS-CoV-2. Schoof and colleagues screened a yeast surface display of synthetic nanobodies, while Xiang and colleagues screened anti-spike nanobodies produced by a llama.
Both papers describe nanobodies that bind tightly to the spike and efficiently neutralize SARS-CoV-2 in cells. Xiang et al note that thermostable nanobodies they developed can be rapidly produced in bulk from microbes. "We envision that the nanobody technology described here will contribute to curbing the current pandemic and possibly a future event," they say.